The proposed e-cigarette regulations of the U.S. Food and Drug Administration (FDA) could face legal challenges on at least five separate grounds if they are enacted without change, a new analysis from ECigIntelligence reveals.
An in-depth report just published by the ECigIntelligence legal team assesses challenges to the scientific foundation of the FDA’s rules as having the best chances of success in court, partly thanks to the agency’s own admission of its ignorance on many key questions.
The report also suggests that specific elements of the so-called “deeming regulations”, such as health warning labels and the cut-off date for the simpler “substantial equivalence” route to product approval, could be open to dispute.
It cites earlier major victories by the tobacco industry against the FDA as demonstrations that the agency can be taken on and defeated.
“FDA regulations are not impervious to challenge, and it is possible that parts of the regulations could be overturned – health warnings for e-cigs could be set aside, for example,” the report says.
“Indeed, courts could prevent the application of the regulations to e-cigs altogether – for example, if e-cig companies are successful with a claim that the regulations are not based on sound scientific evidence.”
At the very least, it adds, “the regulations or a significant part of them may well be put on hold while litigation is pending”.
What This Means: With the regulations themselves quite likely to be altered before coming into force, and the FDA recently having extended the comment period on them precisely in order to hear proposals for changes, it is far too early to say exactly what next legal steps e-cigarette companies might take. But for those who feel the deeming regs impose unacceptable burdens on the new industry, the battle is clearly far from over, as this report shows.
– Barnaby Page ECigIntelligence staff
ECigIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of ECigIntelligence, does not accept any liability or responsibility for information or views published.
Please see this page for a detailed description of our methodology.